Brokerage Firm Rating on OncoGenex Pharmaceuticals (OGXI)

OncoGenex Pharmaceuticals (OGXI) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 1 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

OncoGenex Pharmaceuticals (OGXI) : 2 Wall Street analysts covering OncoGenex Pharmaceuticals (OGXI) believe that the average level the stock could reach for the short term is $3.5. The maximum price target given is $4 and the minimum target for short term is around $3, hence the standard deviation is calculated at $0.71.


For the current week, the company shares have a recommendation consensus of Buy. OncoGenex Pharmaceuticals (NASDAQ:OGXI): The stock opened at $0.86 on Thursday but the bulls could not build on the opening and the stock topped out at $0.91 for the day. The stock traded down to $0.86 during the day, due to lack of any buying support eventually closed down at $0.88 with a loss of -0.33% for the day. The stock had closed at $0.88 on the previous day. The total traded volume was 45,629 shares.

In a related news, The Securities and Exchange Commission has divulged that Jacobs Cindy, officer (EVP, CMO) of Oncogenex Pharmaceuticals, Inc., had unloaded 1,437 shares at an average price of $1.02 in a transaction dated on June 13, 2016. The total value of the transaction was worth $1,466.

OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has three product candidates in its pipeline: custirsen, apatorsen and OGX-225. Of the product candidates in its pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two Phase III studies and five Phase II studies. These product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.